Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1192 in ANCA Associated Vasculitis
NCT07033299Phase 1Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT1192 in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Primary endpoints: Safety and tolerability of CT1192 at 12 months and Maximum Tolerable Dose at 28 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
CT1192
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07033299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033299.